... Food and Drug Administration Breyanzi — U.S. Food and Drug Administration Kymriah — U.S. ...
... Your oncologist (cancer doctor) may recommend: Another targeted therapy, such as acalabrutinib (Calquence), pirtobrutinib (Jaypirca), venetoclax (Venclexta) — which is used off-label — or zanubrutinib (Brukinsa) Chimeric antigen receptor (CAR) T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi) Chemotherapies ...
Mantle Cell Lymphoma Stages: Are Most People Diagnosed at Stage 4?
... Your oncologist (cancer doctor) may recommend: Another targeted therapy, such as acalabrutinib (Calquence), pirtobrutinib (Jaypirca), venetoclax (Venclexta) — which is used off-label — or zanubrutinib (Brukinsa) Chimeric antigen receptor (CAR) T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi) Chemotherapies ...
... Some examples of CAR T-cell therapy include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesBispecific antibodies are a new type of drug with two parts. ...
... When CAR T cells find cancer cells, they attach to them and kill them.Several CAR T-cell therapies are approved for people with relapsed DLBCL after they have tried other treatments: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) These CAR T-cell therapies show consistent responses in clinical trials ...
5 Facts To Know About Large B-Cell Lymphoma: Symptoms, Treatments, and More
... When CAR T cells find cancer cells, they attach to them and kill them.Several CAR T-cell therapies are approved for people with relapsed DLBCL after they have tried other treatments: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) These CAR T-cell therapies show consistent responses in clinical trials ...
... Three CAR T-cell therapy drugs have been approved to treat DLBCL, including: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesBispecific antibody treatments are another type of immunotherapy that are showing promising results, including epcoritamab-bysp (Epkinly) and glofitamab-gxbm ...
Remission and Complete Response in DLBCL: How Long It Lasts and More
... Three CAR T-cell therapy drugs have been approved to treat DLBCL, including: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesBispecific antibody treatments are another type of immunotherapy that are showing promising results, including epcoritamab-bysp (Epkinly) and glofitamab-gxbm ...
... FDA-approved CAR T-cell therapies include: Axicabtagene ciloleucel (Yescarta) — Used for certain types of large B-cell lymphoma, follicular lymphoma, and as a second-line treatment for large B-cell lymphoma Brexucabtagene autoleucel (Tecartus) — Approved for mantle cell lymphoma Liscocabtagene maraleucel (Breyanzi) — Approved for large B-cell lymphoma ...
Immunotherapy for Lymphoma: 4 Points To Know
... FDA-approved CAR T-cell therapies include: Axicabtagene ciloleucel (Yescarta) — Used for certain types of large B-cell lymphoma, follicular lymphoma, and as a second-line treatment for large B-cell lymphoma Brexucabtagene autoleucel (Tecartus) — Approved for mantle cell lymphoma Liscocabtagene maraleucel (Breyanzi) — Approved for large B-cell lymphoma ...
... Several other drugs have recently been approved specifically for treatment of relapsed or refractory follicular lymphoma: Tisagenlecleucel (Kymriah) — Approved in May 2022 Mosunetuzumab-axgb (Lunsumio) — Approved in December 2022 Zanubrutinib (Brukinsa) — Approved in March 2024 Lisocabtagene maraleucel (Breyanzi) — Approved in May 2024 Epcoritamab-bysp ...
Follicular Lymphoma Stages and Grades: What To Expect With Progression
... Several other drugs have recently been approved specifically for treatment of relapsed or refractory follicular lymphoma: Tisagenlecleucel (Kymriah) — Approved in May 2022 Mosunetuzumab-axgb (Lunsumio) — Approved in December 2022 Zanubrutinib (Brukinsa) — Approved in March 2024 Lisocabtagene maraleucel (Breyanzi) — Approved in May 2024 Epcoritamab-bysp ...
... Some options include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) CAR T-cell therapy can lead to strong and long-lasting remissions (periods of no active disease), even after other drugs stopped working. Possible side effects may include fever, low blood pressure, or confusion. ...
6 Treatments for Large B-Cell Lymphoma
... Some options include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) CAR T-cell therapy can lead to strong and long-lasting remissions (periods of no active disease), even after other drugs stopped working. Possible side effects may include fever, low blood pressure, or confusion. ...
... Examples of anti-CD19 therapies approved for treating DLBCL include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesIn 2023, the U.S. ...
DLBCL Relapse Rate and Treatment Options
... Examples of anti-CD19 therapies approved for treating DLBCL include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesIn 2023, the U.S. ...
... Some examples of CAR T-cell therapy include: Tisagenlecleucel (Kymriah) Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Bispecific AntibodiesIn 2023, two bispecific antibodies were approved to treat relapsed/refractory DLBCL that hasn’t responded to other treatments. ...
Early vs. Advanced DLBCL: How Are They Treated Differently?
... Some examples of CAR T-cell therapy include: Tisagenlecleucel (Kymriah) Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Bispecific AntibodiesIn 2023, two bispecific antibodies were approved to treat relapsed/refractory DLBCL that hasn’t responded to other treatments. ...